Ondansetron in the Prevention of Hypotension in Patients Undergoing Spinal Anesthesia
Status:
Unknown status
Trial end date:
2020-03-01
Target enrollment:
Participant gender:
Summary
Ondansetron, a potent 5-HT 3 receptor antagonist commonly used as an antiemetic. The main
objective of the present study is to verify the hypothesis that blocking type 3 serotonin
receptors with intravenous ondansetron reduces the incidence of spinal anesthesia-induced
hypotension